gene therapy

8 statements across 6 episodes · 5 bullish · 0 bearish · 4 people on the record · first statement Dec 22, 2018 by Jorge Conde · across every show →

Everything said about gene therapy, oldest first

Dec 22, 2018 positive
Assertion Partly supported
The first approved gene therapy treated a rare form of blindness
“And last year saw the approval of the first gene therapy for a treatment of a rare form of blindness.”
Jorge Conde Dec 22, 2018 ▶ 11:04 Programming Medicine
Dec 22, 2018 neutral
Assertion Supported
Around 5,000 known diseases are caused by single-gene mutations
“So gene therapy has been the holy grail for treating the approximately 5000 known diseases that are caused by a single gene mutation.”
Jorge Conde Dec 22, 2018 ▶ 10:13 Programming Medicine
Dec 22, 2018 bullish
Prediction Not checkable as stated
Precise editing and better delivery will expand gene therapy applications
“So as we advance our ability to deliver gene therapy, as we advance our ability to actually very precisely edit the genes, and only the genes that we need to edit, gene therapy will become applicable to a far broader range of diseases, not just limited to thos…”
Jorge Conde Dec 22, 2018 ▶ 12:36 Programming Medicine
Jan 2, 2019 positive
Assertion Partly supported
Conde: FDA advisory panels passed gene therapy and CAR-T unanimously 13-0
“Gene therapy, an area that historically has been considered to be very risky, has been shown to be so effective in this form of treating inheritable form of blindness, That that passed the FDA panel recommendation unanimously, a 13 to zero vote. CAR T similarl…”
Jorge Conde Jan 2, 2019 ▶ 21:59 a16z Podcast | Taking the Pulse on Bio
Jan 17, 2019
Assertion Partly supported
Novartis spent $15 billion on gene therapy acquisitions in 2018
“We've done fifteen billion dollars of acquisitions just last year in the space, not, not including all of our internal work in each of these areas.”
Vas Narasimhan Jan 17, 2019 ▶ 17:24 a16z Podcast | The Science and Business of Innovative Medicines
Feb 28, 2019 positive
Insight
Chang: Gene therapy modalities create moats providing sustained cash flows
“If you actually think about gene therapy and new technologies, they are creating the moat. Meaning, for example, Avexis and SMA, they are the, probably the leading gene therapy program out there, and they want to continue building that franchise and have not o…”
Nate Chang Feb 28, 2019 ▶ 4:17 What’s with All the Bio M&A in 2019?: A Quick Take
Oct 5, 2019 neutral
Assertion Contradicted
Andy Tran: AAVs are the only clinically approved gene therapy vectors
“To jump in, probably the natural place to start is on the AV side, as these adeno-associated viruses are the only clinically approved vector so far for gene therapy.”
Andy Tran Oct 5, 2019 ▶ 12:24 CRISPR 2.0 and the Future of Gene Therapies
Dec 12, 2023 positive
Insight
Gene therapy delivery platforms enable modular repurposing across different diseases
“If we're able to make a medicine that does that, that can deliver one gene to a given cell type, it becomes increasingly likely that we'll be able to deliver a different gene to a different cell type for a different disease.”
Jorge Conde Dec 12, 2023 ▶ 7:19 Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.